$MRZM
Marizyme Inc Stock $mrzm

$mrzm Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223029436 Filed on August 18, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$181.5K	$184.7K	$61.81K
YoY Change	138.82%	198.89%	-61.56%
Cost Of Revenue	$50.99K	$49.61K	$11.03K
YoY Change	228.96%	349.78%	-92.65%
Gross Profit	$130.5K	$135.1K	$50.78K
YoY Change	115.74%	166.1%	-40.03%
Gross Profit Margin	71.91%	73.15%	82.16%
Selling, General & Admin	$4.272M	$3.875M	$3.071M
YoY Change	210.71%	26.2%	-27.05%
% of Gross Profit	3272.57%	2867.92%	6047.09%
Research & Development	$492.2K	$691.4K	$1.371M
YoY Change	-30.5%	-49.59%	460.5%
% of Gross Profit	377.06%	511.66%	2700.81%
Depreciation & Amortization	$210.3K	$210.3K	$210.4K
YoY Change	-0.03%	-0.03%
% of Gross Profit	161.08%	155.62%	414.26%
Operating Expenses	$4.988M	$4.939M	$4.664M
YoY Change	116.01%	5.91%	124.91%
Operating Profit	-$4.857M	-$4.804M	-$4.602M
YoY Change	117.52%	4.39%	140.58%
Interest Expense	-$7.406M	-$13.42M	-$530.2K
YoY Change	813.6%	2431.76%	12554.65%
% of Operating Profit
Other Income/Expense, Net	-$27.59M	-$15.77M	-$2.322M
YoY Change	-4155.41%	579.19%	-948.11%
Pretax Income	-$32.45M	-$20.58M	-$6.924M
YoY Change	1990.01%	197.18%	79.81%
Income Tax
% Of Pretax Income
Net Earnings	-$32.45M	-$20.58M	-$6.924M
YoY Change	1990.01%	197.18%	322.47%
Net Earnings / Revenue	-17875.49%	-11138.09%	-11202.23%
Basic Earnings Per Share	-$0.71	-$0.48	-$0.17
Diluted Earnings Per Share	-$0.71	-$0.48	-$169.6K
COMMON SHARES
Basic Shares Outstanding	45.67M shares	43.42M shares	40.83M shares
Diluted Shares Outstanding	45.81M shares	43.19M shares	40.83M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$474.9K	$205.2K	$2.045M
YoY Change	-59.83%	-89.96%	97280.0%
Cash & Equivalents	$474.9K	$205.2K	$2.045M
Short-Term Investments
Other Short-Term Assets	$661.4K	$606.4K	$235.4K
YoY Change	-21.25%	157.6%	729.97%
Inventory	$99.02K	$139.7K	$268.4K
Prepaid Expenses	$661.4K	$606.3K	$235.4K
Receivables	$43.22K	$72.98K	$53.08K
Other Receivables	$35.77K	$34.30K	$12.59K
Total Short-Term Assets	$1.314M	$1.059M	$2.614M
YoY Change	-43.87%	-59.51%	1470.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.50K	$12.50K	$12.68K
YoY Change	-0.9%	-1.43%	-98.97%
Goodwill	$7.191M	$7.191M	$7.191M
YoY Change	0.0%	0.0%
Intangibles			$52.45M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$160.0K	$170.8K	$369.1K
YoY Change	-56.65%	-53.71%	-0.51%
Total Long-Term Assets	$35.61M	$35.92M	$61.69M
YoY Change	-42.0%	-41.76%	15.27%
TOTAL ASSETS
Total Short-Term Assets	$1.314M	$1.059M	$2.614M
Total Long-Term Assets	$35.61M	$35.92M	$61.69M
Total Assets	$36.92M	$36.98M	$64.30M
YoY Change	-42.06%	-42.49%	19.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.137M	$2.038M	$617.0K
YoY Change	151.85%	230.29%	-48.97%
Accrued Expenses	$431.4K	$428.8K	$418.3K
YoY Change	2.5%	2.5%	72.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$241.4K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$20.36M	$12.75M	$241.4K
YoY Change	9433.18%	5181.86%
Total Short-Term Liabilities	$48.67M	$20.82M	$1.500M
YoY Change	2930.3%	1287.72%	-12.62%
LONG-TERM LIABILITIES
Long-Term Debt	$38.60K	$307.4K	$843.0K
YoY Change	-97.66%	-63.53%	24053.3%
Other Long-Term Liabilities	$10.16M	$8.583M	$20.61M
YoY Change	-47.95%	-58.35%	92.16%
Total Long-Term Liabilities	$10.20M	$8.890M	$21.45M
YoY Change	-51.82%	-58.56%	99.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.67M	$20.82M	$1.500M
Total Long-Term Liabilities	$10.20M	$8.890M	$21.45M
Total Liabilities	$58.87M	$29.71M	$22.95M
YoY Change	158.45%	29.46%	84.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.6M	-$109.1M	-$60.87M
YoY Change	126.78%	79.26%
Common Stock	$46.67K	$45.37K	$40.83K
YoY Change	14.3%	11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$21.95M	$7.270M	$41.35M
YoY Change
Total Liabilities & Shareholders Equity	$36.92M	$36.98M	$64.30M
YoY Change	-42.06%	-42.49%	19.79%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$32.45M	-$20.58M	-$6.924M
YoY Change	1990.01%	197.18%	322.47%
Depreciation, Depletion And Amortization	$210.3K	$210.3K	$210.4K
YoY Change	-0.03%	-0.03%
Cash From Operating Activities	-$1.153M	-$1.198M	-$2.742M
YoY Change	-47.84%	-56.31%	201.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.423M	1.073M	1.614M
YoY Change	5.56%	-33.5%	2053.36%
NET CHANGE
Cash From Operating Activities	-1.153M	-1.198M	-2.742M
Cash From Investing Activities
Cash From Financing Activities	1.423M	1.073M	1.614M
Net Change In Cash	269.7K	-124.6K	-1.128M
YoY Change	-131.26%	-88.96%	34.99%
FREE CASH FLOW
Cash From Operating Activities	-$1.153M	-$1.198M	-$2.742M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001413754
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2022Q4	MRZM	Convertible Debt Original Issue Discount Current ConvertibleDebtOriginalIssueDiscountCurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
	us-gaap	Royalty Expense RoyaltyExpense		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt		usd
	MRZM	Shares Issued As Part Of Confidential Settlement Agreement SharesIssuedAsPartOfConfidentialSettlementAgreement		usd
	MRZM	Shares Issued For Services SharesIssuedForServices		usd
	MRZM	Warrants Issued As Part Of Promissory Note Agreement WarrantsIssuedAsPartOfPromissoryNoteAgreement		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	MRZM	Warrants Cancelled In Debt Extinguishment WarrantsCancelledInDebtExtinguishment		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold		usd
CY2022Q2	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-53223
	dei	Entity Registrant Name EntityRegistrantName	MARIZYME, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5464863
	dei	Entity Address Address Line1 EntityAddressAddressLine1	555 Heritage Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 205
	dei	Entity Address City Or Town EntityAddressCityOrTown	Jupiter
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33458
	dei	City Area Code CityAreaCode	(561)
	dei	Local Phone Number LocalPhoneNumber	935-9955
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45666760	shares
CY2023Q2	us-gaap	Cash Cash	205226	usd
CY2022Q4	us-gaap	Cash Cash	510865	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72975	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87801	usd
CY2023Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	34306	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15310	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	606347	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1125761	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	139723	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	215566	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	1058577	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1955303	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12500	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12545	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1294442	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27254434	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023Q2	MRZM	Prepaid Royalties Noncurrent PrepaidRoyaltiesNoncurrent	140843	usd
CY2022Q4	MRZM	Prepaid Royalties Noncurrent PrepaidRoyaltiesNoncurrent	339091	usd
CY2023Q2	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	7190656	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	35922875	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	36732335	usd
CY2023Q2	us-gaap	Assets Assets	36981452	usd
CY2022Q4	us-gaap	Assets Assets	38687638	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2038005	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1365443	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	283290	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1132829	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	12316495	usd
CY2023Q2	MRZM	Convertible Debt Original Issue Discount Current ConvertibleDebtOriginalIssueDiscountCurrent	150086	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5461702	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	428789	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20821718	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2921767	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	865653	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2023Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	307425	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	2751633	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4823725	usd
CY2023Q2	MRZM	Contingent Liabilities ContingentLiabilities	7717000	usd
CY2022Q4	MRZM	Contingent Liabilities ContingentLiabilities	9707000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8890078	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18343886	usd
CY2023Q2	us-gaap	Liabilities Liabilities	29711796	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21265653	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45366760	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45366760	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	45366	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40528	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	116344709	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103370890	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109120419	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85989433	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7269656	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36981452	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38687638	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	184739	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61809	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	313713	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61809	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	49611	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	11025	usd
	us-gaap	Cost Of Revenue CostOfRevenue	88886	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11025	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	135128	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	50784	usd
	us-gaap	Gross Profit GrossProfit	224827	usd
	us-gaap	Gross Profit GrossProfit	50784	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	511844	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	873865	usd
	us-gaap	Professional Fees ProfessionalFees	896650	usd
	us-gaap	Professional Fees ProfessionalFees	1417905	usd
CY2023Q2	us-gaap	Salaries And Wages SalariesAndWages	335004	usd
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	902106	usd
	us-gaap	Salaries And Wages SalariesAndWages	601972	usd
	us-gaap	Salaries And Wages SalariesAndWages	1817746	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	691393	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1371470	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1297390	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2589766	usd
CY2023Q2	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	160762	usd
CY2022Q2	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	676242	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	371728	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1392674	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210293	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210361	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	420631	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	420722	usd
CY2023Q2	us-gaap	Royalty Expense RoyaltyExpense	162065	usd
	us-gaap	Royalty Expense RoyaltyExpense	198248	usd
CY2023Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2867749	usd
CY2022Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	618498	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	3375073	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1009070	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	4939110	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4652542	usd
	us-gaap	Operating Expenses OperatingExpenses	7161692	usd
	us-gaap	Operating Expenses OperatingExpenses	8647883	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4803982	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4601758	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6936865	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8597099	usd
CY2023Q2	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	13424169	usd
CY2022Q2	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	530226	usd
	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	15121870	usd
	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	829770	usd
CY2023Q2	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	714000	usd
CY2022Q2	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-1792000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1990000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-3622000	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-684682	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-684682	usd
CY2023Q2	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-2377569	usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-2377569	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15772420	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2322226	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16194121	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4451770	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-20576402	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923984	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23130986	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13048869	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43187439	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43187439	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40828188	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40828188	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41979194	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41979194	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40728740	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40728740	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43187439	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40828188	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41979194	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40728740	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47690332	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	716432	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2969916	usd
CY2022Q1	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6124885	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45254795	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	676242	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2341659	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923984	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41348712	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	210966	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	153600	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15231967	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15231967	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160762	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	223486	usd
CY2023Q2	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	265216	usd
CY2023Q2	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Debt Extinguishment AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnDebtExtinguishment	19058426	usd
CY2023Q2	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Promissory Note AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnPromissoryNote	1333128	usd
CY2023Q2	MRZM	Stock Issued During Period Warrants Cancelled In Debt Extinguishment StockIssuedDuringPeriodWarrantsCancelledInDebtExtinguishment	-8426927	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-20576402	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7269656	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7269656	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23130986	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13048869	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	420631	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	420722	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	371728	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1392674	usd
	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	15121870	usd
	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	829770	usd
	MRZM	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	-1850533	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1990000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-3622000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-684682	usd
	MRZM	Loss On Issuance Of Debt LossOnIssuanceOfDebt	-2377569	usd
	MRZM	Shares Issued As Part Of Confidential Settlement Agreement SharesIssuedAsPartOfConfidentialSettlementAgreement	153600	usd
	MRZM	Shares Issued For Services SharesIssuedForServices	138000	usd
	MRZM	Warrants Issued As Part Of Promissory Note Agreement WarrantsIssuedAsPartOfPromissoryNoteAgreement	1333128	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	4171	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	15715	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-519414	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-21787	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-75843	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	246060	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1467328	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-973544	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	143351	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-908973	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2318013	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7055675	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	870000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5120743	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	265216	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	877158	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-95431	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2012374	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5028312	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-305639	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2027363	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	510865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4072339	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	205226	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2044976	usd
	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	5461702	usd
	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	1938379	usd
	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	19058426	usd
	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	3461042	usd
	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	2064133	usd
	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	278678	usd
	MRZM	Warrants Cancelled In Debt Extinguishment WarrantsCancelledInDebtExtinguishment	8426927	usd
	us-gaap	Stock Issued1 StockIssued1	84140	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109120419	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85989433	usd
CY2023Q2	MRZM	Working Capital WorkingCapital	19763141	usd
CY2022Q4	MRZM	Working Capital WorkingCapital	966464	usd
CY2023Q2	us-gaap	Cash Cash	205226	usd
CY2022Q4	us-gaap	Cash Cash	510865	usd
CY2023Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1203537	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	535717	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zrv9ow3F09h1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zmNFz8UTnIo7">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities and contingent liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	MRZM	Midrange Average Estimated Interest Rate MidrangeAverageEstimatedInterestRate	0.206	pure
CY2023Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	129000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	796000	usd
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	293000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	772000	usd
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	4606000	usd
CY2022	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	5402000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	266034	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1356797	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	62355	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1294442	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29142745	usd
CY2020Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	five-and-a-half-year lease agreement
CY2020Q4	us-gaap	Area Of Land AreaOfLand	10300	sqft
CY2022Q2	us-gaap	Area Of Land AreaOfLand	3053	sqft
CY2023Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y29D
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	37674	usd
	us-gaap	Payments For Rent PaymentsForRent	192502	usd
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	110353	usd
	us-gaap	Payments For Rent PaymentsForRent	221253	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1294442	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1485023	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	428789	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	423495	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	865653	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1061528	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1294442	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1485023	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	211747	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	434082	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	444934	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1888311	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27254434	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	53492745	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1467725	usd
CY2022Q4	MRZM	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-24350000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023Q2	us-gaap	Goodwill Goodwill	7190656	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	52866192	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	24350000	usd
CY2022	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	841172	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	420586	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27254434	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	9578040	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	14705890	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4260594	shares
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6692765	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4180071	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6500743	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-684682	usd
	MRZM	Adjustments To Additional Paid In Capital Issuance Of Warrants On Debt Extinguishment AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsOnDebtExtinguishment	19058426	usd
CY2023Q2	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	5730714	usd
	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	7286891	usd
CY2022Q2	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	524884	usd
	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	816881	usd
CY2023Q2	MRZM	Accrued Interest Payable Price Per Share AccruedInterestPayablePricePerShare	0.10
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45366760	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45366760	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528191	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3650943	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.20
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	62502	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	62498	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y21D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M21D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3479831	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M1D
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	295750	usd
	MRZM	Share Based Compensation Arrangement By Share Based Payment Award Non Option Derivative Liabilities Extinguished ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionDerivativeLiabilitiesExtinguished	355577447	usd
	MRZM	Share Based Compensation Arrangements By Share Based Payment Award Non Options Derivative Liabilities Extinguished ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsDerivativeLiabilitiesExtinguished	0.10
CY2023Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1333127	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	160762	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	371728	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	676242	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1392674	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	12621	usd
CY2019Q3	MRZM	Royalties Percentage RoyaltiesPercentage	0.10	pure

Files In Submission

Name	View Source	Status
mrzm-20230630_cal.xml	Edgar Link	unprocessable
mrzm-20230630_def.xml	Edgar Link	unprocessable
0001493152-23-029436-index-headers.html	Edgar Link	pending
0001493152-23-029436-index.html	Edgar Link	pending
0001493152-23-029436.txt	Edgar Link	pending
0001493152-23-029436-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex3-15.htm	Edgar Link	pending
ex3-15_001.jpg	Edgar Link	pending
ex3-15_002.jpg	Edgar Link	pending
ex3-15_003.jpg	Edgar Link	pending
ex3-15_004.jpg	Edgar Link	pending
ex3-15_005.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrzm-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
mrzm-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mrzm-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRZM
Marizyme Inc Stock $mrzm

2023 Q3 Form 10-Q Financial Statement

#000149315223029436 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM Marizyme Inc Stock $mrzm

2023 Q3 Form 10-Q Financial Statement

#000149315223029436 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM
Marizyme Inc Stock $mrzm